Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases

Bayer (BAYRY) received a positive opinion from the EMA's CHMP recommending label extension for Eylea 8 mg in the EU, potentially allowing for treatment intervals of up to six months for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). If approved, Eylea 8 mg would be the only anti-VEGF therapy in the EU offering such extended intervals for both conditions, potentially improving patient compliance; this is supported by three-year study results showing maintained visual and anatomical improvements. Year-to-date, Bayer shares have surged 41.8% against the industry’s decline of 5.2%.

Analysis

Bayer has received a significant positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending a label extension for its Eylea 8 mg (aflibercept) treatment in the European Union. This recommendation, pending final European Commission approval anticipated in the coming weeks, would allow for treatment intervals of up to six months for both neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). If approved, Eylea 8 mg would become the only anti-VEGF therapy in the EU offering such extended dosing intervals for both major retinal conditions, a development poised to significantly enhance patient compliance and treatment adherence by reducing injection frequency and clinic visits. The CHMP's favorable stance is substantiated by positive three-year results from the pivotal PULSAR (nAMD) and PHOTON (DME) studies, which demonstrated maintained visual and anatomical improvements; by the end of these studies, 24% of nAMD and 28% of DME patients reached a final dosing interval of six months. Furthermore, Eylea 8 mg maintained a favorable safety profile consistent with the well-established Eylea 2 mg, with no new safety concerns identified. This regulatory milestone is particularly crucial for Bayer's HealthCare unit, given Eylea's status as a blockbuster drug co-developed with Regeneron (REGN), where Bayer records net product sales outside the United States. The news aligns with Bayer's strong stock performance, with shares having surged 41.8% year-to-date, substantially outperforming the industry’s 5.2% decline.

Key Decisions for Investors

• Investors should closely monitor the European Commission's final decision, as approval would solidify Eylea 8 mg's competitive positioning and bolster Bayer's revenue stream from ex-US sales.
• Consider the potential for increased market share capture in the EU retinal disease market for Bayer, should Eylea 8mg become the only therapy offering six-month treatment intervals for both nAMD and DME.
• Evaluate this positive regulatory development in the context of Bayer's significant year-to-date stock outperformance, as it may provide further support for the current valuation and investor sentiment.